Fisher Asset Management LLC Invests $4.07 Million in Revvity, Inc. (NYSE:RVTY)

Fisher Asset Management LLC purchased a new stake in shares of Revvity, Inc. (NYSE:RVTY) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 37,203 shares of the company’s stock, valued at approximately $4,067,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Parkside Financial Bank & Trust purchased a new stake in shares of Revvity in the 4th quarter worth about $25,000. Gladius Capital Management LP boosted its position in Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after acquiring an additional 106 shares in the last quarter. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Revvity during the 4th quarter worth approximately $27,000. CENTRAL TRUST Co bought a new position in shares of Revvity in the 4th quarter worth approximately $27,000. Finally, ORG Partners LLC purchased a new position in shares of Revvity in the 4th quarter valued at approximately $32,000. Institutional investors own 86.65% of the company’s stock.

Revvity Stock Up 0.2 %

Revvity stock opened at $107.50 on Friday. The firm has a market cap of $13.26 billion, a price-to-earnings ratio of 88.84, a PEG ratio of 2.79 and a beta of 1.08. The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a 12 month low of $79.50 and a 12 month high of $131.96. The stock has a fifty day simple moving average of $106.61 and a two-hundred day simple moving average of $105.57.

Revvity (NYSE:RVTY) last issued its earnings results on Monday, April 29th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. The business had revenue of $649.90 million during the quarter, compared to analyst estimates of $646.83 million. Revvity had a return on equity of 7.37% and a net margin of 5.49%. Revvity’s revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.01 EPS. Equities analysts predict that Revvity, Inc. will post 4.65 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.26%. The ex-dividend date is Friday, July 19th. Revvity’s dividend payout ratio is currently 23.14%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Robert W. Baird increased their price objective on Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a report on Tuesday, April 30th. Jefferies Financial Group started coverage on shares of Revvity in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target for the company. Finally, TD Cowen upped their price objective on shares of Revvity from $123.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Revvity has a consensus rating of “Moderate Buy” and an average target price of $117.92.

Insiders Place Their Bets

In other news, insider Joel S. Goldberg sold 4,000 shares of the firm’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $110.46, for a total value of $441,840.00. Following the transaction, the insider now directly owns 36,900 shares in the company, valued at approximately $4,075,974. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.60% of the stock is currently owned by insiders.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.